Imbruvica (Ibrutinib) 140 mg – Targeted Therapy for Blood Cancer Imbruvica (Ibrutinib)

Imbruvica (Ibrutinib) is a targeted therapy used in the treatment of certain types of blood cancers. It belongs to a class of drugs known as BTK inhibitors, which act on abnormal lymphatic cancer cells with high precision.

What is Imbruvica (Ibrutinib)?

Imbruvica is part of the Bruton’s Tyrosine Kinase (BTK) inhibitors family, which are enzymes involved in the growth and survival of certain cancerous blood cells.

In some blood cancers, BTK signaling is overactive, leading to uncontrolled cell growth. Imbruvica works by:

• Blocking abnormal cancer cell signaling
• Reducing proliferation of malignant lymphocytes
• Helping control disease progression

In simple terms:
It targets the internal survival pathway of blood cancer cells.

Indications

Imbruvica (Ibrutinib) is used in:

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Other lymphoid malignancies depending on protocol

Dosage and Administration

• Dose depends on condition and protocol (e.g., 140 mg or combination regimens)
• Taken orally
• Usually once daily
• Should be taken at the same time every day
• Treatment duration is determined by the physician

Common Side Effects

May include:

• Fatigue
• Diarrhea
• Mild bruising or bleeding
• Muscle pain
• Low blood cell counts
• Mild infections

Rarely: cardiac or bleeding complications requiring close monitoring.

Monitoring During Treatment

Patients on Imbruvica (Ibrutinib) require:

• Complete blood count monitoring
• Assessment for bleeding or infection
• Liver function tests
• Evaluation of treatment response

Availability & How to Access Treatment

Imbruvica (Ibrutinib) is available through Macrocare’s approved partners.

You can now request and access the medication easily through us.

WhatsApp contact for medication requests:
Click here

Imbruvica (Ibrutinib) Imbruvica (Ibrutinib) 140 mg is an effective targeted therapy for blood cancers such as CLL, SLL, and MCL, working by blocking cancer cell survival signals and improving disease control.

Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.